6 RESULTS
COMMENT The press release is promising. The nature of press releases is to simplify and put a rosy spin on things, and we have seen puff-piece press releases in the past. I am therefore eager to see more details. Specific concerns relate to how analyses were done
COMMENT I am pleased that Dr. Shen and Biogen have taken up our invitation to add internal and new data to our prior meta-analysis (Ackley et al., 2021), and I look forward to seeing their detailed methods. Our analyses showed the potential power of pooled analys
COMMENT The CMS's proposed decision strikes me as wise and indicative of their interest in covering medications that help people. Their decision proposes a structure that will rapidly deliver rigorous evidence on whether medications such as Aduhelm have any
COMMENT Numerous pragmatic study options would be possible for ICARE-AD to have a more direct comparison group. Any type of randomized wait list would provide much more rigorous and convincing evidence than historical controls or any version of the Conrado et al.
COMMENT The data did not support this approval. The advisory committee did a thorough and independent review and came to the same conclusion countless independent scientists have also voiced: The clinical efficacy findings are no more convincing than a roll of di
COMMENT This study addresses an extremely important topic and highlights how much uncertainty there still is about the impact of BMI across the life course on AD risk. The most relevant questions for most people interested in this research are: Would losing weigh
